14 Einstein Street
Ness Ziona 7403618
Israel
972 8 662 3301
https://www.enlivex.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees:
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Shai Novik M.B.A. | Executive Chairman | 528k | N/A | 1966 |
Dr. Oren Hershkovitz Ph.D. | Chief Executive Officer | 273.6k | N/A | 1977 |
Prof. Dror Mevorach M.D. | Founder and Chief Scientific & Medical Officer | 180k | N/A | 1956 |
Ms. Shachar Shlosberger CPA | Chief Financial Officer | 126k | N/A | 1977 |
Mr. Veronique Amor-Baroukh | Senior Director of Operations | N/A | N/A | N/A |
Ms. Sigal Arad | Director of HR | N/A | N/A | N/A |
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. The company has a collaboration agreement with BeiGene to evaluate the safety and efficacy of Allocetra in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor for the treatment of patients with advanced-stage solid tumors. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.
Enlivex Therapeutics Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.